- Human pathology

Home > A. Molecular pathology > Targeted therapy > Small molecules > regorafenib


Monday 5 March 2012

The small molecule regorafenib is an anti-VEGFR.

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer.

Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

See also